Dear Sir/Madam, Please find the attached disclosure under Regulation 31(4) of SEBI (SAST) Regulations, 2011. Thanking You.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prism Medico and Pharmacy Ltd has filed its annual SEBI SAST Regulation 31(4) disclosure for FY2024-25 with BSE and MSEI. The promoters and persons acting in concert have confirmed that none of them created any new encumbrance (pledge, lien, or similar) on their shares during the financial year ended 31 March 2025. One promoter entity, Symbiosis Pharmaceuticals Private Limited, has signed the confirmation on behalf of the promoter group. The filing is a routine annual compliance submission and indicates no change in the encumbered status of promoter holdings.
This is a routine compliance filing confirming no new pledging activity by promoters; it carries no material impact on the stock price or shareholder value, though it provides mild reassurance that promoters have not increased leverage on their holdings.